Progenika Biopharma S.a.

Bioiberica, S.a.

Oncomatryx Biopharma, S.l.

Proteomike, S.l.

Juste S.a.q.f.

Laureano Simón Buela

Antonio Martínez Martínez

Diego Tejedor Hernández

Antonio Martinez Martinez

Daniel Nagore Casas

Diego Tejedor Hernandez

Monica Lopez Martinez

Elisa Jimenez Uribe

Miguel Molina Vila

Jorge Cuevas González

José Javier Gómez Román

Corina Junquera Sánchez-Vallejo

María Pilar Sáenz Jiménez

Simon Santa Cruz

Marta Artieda Osenalde

Marta Artieda Oseñalde

Monica López Martínez

Elisa Jiménez Uribe

Lorena Hernandez Garcia

Lorena Hernández García

Amagoia Ametzazurra

Ainhoa Ruiz Del Agua

Luis Barneo Serra

Carmen Garcia Pravia

Juan Ramon De Los Toyos Gonzalez

Marcos Garcia Ocana

Jose Fernando Vazquez Villa

Jokin Del Amo Iribarren

Jokin Del Amo

Juan Morote Robles

Arrate Eguiara

Daniel Nagore

Ainara Cadaval

Nelson Fuentes Martinez

Jorge Ochoa Garay

José Fernando Val Bernal

Maria Pilar Sáenz Jiménez

Corina Junquera Sanchez-Vallejo

Cristina Sanz Ibayondo

Antonio Martíinez Martínez

Maria Eladia Argüelles Sánchez

Javier GÓMEZ Roman

Francisco Javier Freire Salinas

Saioa Dominguez Hormaetxe

Antonio Martínez

The invention relates to the field of personalized therapy and, in particular, to a method for classifying a patient suffering from rheumatoid arthritis as a responder or as a non-responder patient to a treatment based on a biological drug.

Method to optimize the treatment of patients with biological drugs

The present invention relates to in vitro methods and products for detecting the presence of an invasive carcinoma in an individual, for determining and/or predicting the stage and/or invasiveness of said carcinoma in an individual, or for monitoring the effect of the therapy administered to an individual who has said carcinoma based on col11a1 gene and proCOL11A1 protein expression. The invention also relates to the search for, identification, development and evaluation of the efficacy of compounds for therapy for said carcinoma, for the purpose of developing new medicinal products. The invention also relates to agents inhibiting proCOL11A1 protein expression and/or activity, and/or the effects of this expression.

Methods and products for in vitro diagnosis, in vitro prognosis and the development of drugs against invasive carcinomas

A method for prognosing recurrence of prostate cancer (PCa) in a subject following prostatectomy using the outcomes of selected single nucleotide polymorphisms (SNPs) and clinical variables. A method for genotyping PCa associated genetic variations comprising use of a DNA microarray. A microarray for use in the described methods.

Prognostic method

A method for prognosing a rheumatoid arthritis phenotype using the outcomes of selected single nucleotide polymorphisms (SNPs) and clinical variables. A method for genotyping multiple rheumatoid arthritis associated genetic variations comprising use of a DNA microrarray. A microarray for use in the described methods.

Methods of prognosing a rheumatoid arthritis remission phenotype

The present invention refers to a group of biomarkers and to non-invasive in vitro methods for the diagnosis or prognosis of endometriosis, as well as to a kit to perform said methods.

Detection of endometrial secretion markers for assessment of endometriosis

A method for prognosing osteoporosis phenotypes or estimating osteoporosis quantitative traits comprising determining outcomes for selected SNP variables and clinical variables. Products and methods for genotyping multiple osteoporosis associated genetic variations.

Diagnostic method

An in vitro method for genotyping genetic variations in an individual, and products for use in the method.

Methods and products for in vitro genotyping

The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.

In vitro method to detect bladder transitional cell carcinoma

An in vitro method for genotyping genetic variations in a individual, and products for use in the method.

Growing community of inventors

Derio, Spain

Laureano Simón Buela